Moreover, RMC-4630 is being tested in combination with the MEK inhibitor cobimetinib, which has shown some preliminary evidence of antitumour activity in KRAS-mutated CRC, as indicated by tumour reduction in 37.5% of patients (three of eight). The gene discussed is KRAS; the disease is neoplasm.